Furthermore, the realm of adoptive immunotherapy has unveiled promising prospects, wherein engineered T cells expressing receptors derived from tumor-reactive CD8 T cells demonstrate the potential for neoplasm regression [15,16]. Here, CD8A is linked to neoplasm.